- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10.24 | Notable Labs meldet Insolvenz an, Vorstand tritt zurück | 3 | Investing.com Deutsch | ||
| 15.10.24 | Notable Labs files for bankruptcy, board resigns | 2 | Investing.com | ||
| NOTABLE LABS Aktie jetzt für 0€ handeln | |||||
| 15.10.24 | Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug | 4 | FierceBiotech | ||
| 15.10.24 | Notable Labs, Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 10.10.24 | Notable Labs-Aktie erreicht 52-Wochen-Tief bei 0,38 US-Dollar | 1 | Investing.com Deutsch | ||
| 02.10.24 | Notable Labs stock touches 52-week low at $0.4 amid sharp annual decline | 3 | Investing.com | ||
| 02.10.24 | Notable Labs-Aktie erreicht 52-Wochen-Tief bei 0,4 US-Dollar | - | Investing.com Deutsch | ||
| 20.09.24 | Notable Labs-Aktie erreicht 52-Wochen-Tief bei 0,44 US-Dollar | 1 | Investing.com Deutsch | ||
| 20.09.24 | Notable Labs stock touches 52-week low at $0.44 amid market challenges | 1 | Investing.com | ||
| 20.09.24 | Notable Labs-Aktie unter Druck: Aussichten für Volasertib trüben sich ein - JMP | 1 | Investing.com Deutsch | ||
| 20.09.24 | Notable Labs stock under pressure as volasertib outlook dims - JMP | 1 | Investing.com | ||
| 19.09.24 | Notable Labs announces workforce reduction and strategic shift | 1 | Investing.com | ||
| 17.09.24 | Notable Labs appoints new interim CEO and restructuring officer | 1 | Investing.com | ||
| 16.09.24 | Notable Labs, Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.08.24 | Notable Labs to Present Data on September 4th at SOHO 2024 | 1 | GlobeNewswire (USA) | ||
| 26.08.24 | Notable Labs, Ltd. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 26.08.24 | Notable Labs, Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.08.24 | Notable Labs CEO steps down | 1 | Seeking Alpha | ||
| 26.08.24 | Notable Labs Announces CEO Transition | 144 | GlobeNewswire (Europe) | Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE... ► Artikel lesen | |
| 14.08.24 | Notable Labs, Ltd. - 10-Q, Quarterly Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QUANTUM-SI | 4,285 | +0,59 % | Quantum-Si stock plunges on $50M direct offering terms | ||
| TEMPUS AI | 38,260 | 0,00 % | Tempus AI, Inc.: Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024 | Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the... ► Artikel lesen | |
| QIAGEN | 43,320 | -0,44 % | Biotech Report: Evotec legen zu, Qiagen geben ab | (shareribs.com) Frankfurt / New York 03.01.2025 - Biotech-Aktien konnten am Freitag teilweise zulegen. Für Qiagen ging es leicht abwärts. An der Wall Street tendierte der Sektor überwiegend positiv.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,790 | +8,04 % | Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 8.1% - Still a Buy? | ||
| JANUX THERAPEUTICS | 53,91 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,430 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 7,880 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients | 56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS 89% of patients had >50% decrease in serum tryptase by... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,245 | 0,00 % | Why Is Summit Therapeutics Inc. (SMMT) Among the Best Multibagger Stocks to Buy Right Now? | ||
| EVOTEC | 8,600 | +0,70 % | Deal-Aus verdaut? Evotec sucht Stabilität | Die Evotec-Aktie blickt auf ein turbulentes Jahr zurück. Nach einer Gewinnwarnung und dem Platzen eines milliardenschweren Deals erlebte das Biotech-Unternehmen einen erheblichen Rückschlag. Doch jüngste... ► Artikel lesen | |
| BIONTECH | 113,20 | +0,71 % | Wer wird Favorit in 2025? BioNTech, Pfizer, Vidac Pharma | Der Dezember 2024 war von neuen Rekorden an den Aktienmärkten gekennzeichnet. Der Dow Jones, S&P 500, Nasdaq wie auch der DAX erreichten neue Allzeithochs. Doch einsetzende Gewinnmitnahmen und Kursabsicherungen... ► Artikel lesen | |
| CG ONCOLOGY | 30,500 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | - Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 55,61 | 0,00 % | Tarsus Pharmaceutical - Eye Care Therapeutics | ||
| AVIDITY BIOSCIENCES | 30,600 | -1,86 % | Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now? | ||
| ARCELLX | 79,12 | 0,00 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 5,930 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones | Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient... ► Artikel lesen |
Das Unternehmen NOTABLE LABS LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,04 % bei einem Aktienkurs von 0,248 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NOTABLE LABS LTD finden Sie auf Wallstreet Online.
